Highlighted Research Articles

The naked mole rat (NMR) is a long-lived species reported to display a resistance to cancer development. However, these observations have not been experimentally tested in vivo through a genetically defined model of tumorigenesis. To address this, Shepard, Lester, and colleagues aimed to develop an autochthonous model of lung cancer in the NMR, using CRISPR-mediated genome editing to introduce an oncogenic Eml4–Alk fusion gene and induce the loss of the p53 and pRb tumor suppressors. The findings of this study suggest that the nature and number of events required for tumorigenesis in the lungs of the NMR are likely to be comparable to the requirements for cellular transformation that are present in human cells.See article, p. 35.Diaz-Jimenez, Shuldiner, and colleagues interrogated the oncogenic roles of distinct EML4–ALK fusion variants, which are key drivers of non-small cell lung cancer. Through in vivo and genomic approaches, common variants were shown to not function identically. Instead, each variant engaged unique, variant-specific genetic interactions that dictated the variant’s oncogenic potency and how the variant promoted lung tumorigenesis. Variant-dependent signaling promoted tumor progression and created differential dependencies that may be exploited therapeutically. These findings underscore the potential value of assessing specific EML4–ALK variants to better inform precise oncology strategies.See article, p. 46.Pancreatic cancer is often diagnosed at late stages, limiting treatment opportunities and contributing to poor survival. Wang, Wang, Zhang, and colleagues report the development and prospective validation of a noninvasive, cell-free DNA (cfDNA)-based model that analyzes fragmentation patterns derived from low-pass whole-genome sequencing. In a real-world cohort of 1,926 individuals with diabetes or obesity, the model detected 75% of pancreatic cancers, including all stage 0 cases, with up to 298 days of lead time, significantly outperforming detection via CA19-9. These findings highlight the promise of cfDNA-based screening as a scalable, non-invasive approach for early pancreatic cancer detection, with potential to inform clinical decision-making and improve patient outcomes.See article, p. 66.In this study, Siegel and colleagues report the preclinical activity of sevabertinib, a potent and reversible dual EGFR/HER2 inhibitor, in cancer models harboring alterations of ERBB2, which encodes HER2. The ERBB2 alterations included exon 20 insertions, point mutations, and amplifications, as well as translocations of the ERBB family ligand, neuregulin-1. Moreover, the study reported patient responses to sevabertinib from a phase I/II clinical trial, indicating potential benefit for patients with HER2-mutant lung cancer. Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions, and these data position sevabertinib as such an option.See article, p. 81.Although links between the microbiome and immunotherapy outcomes are well recognized, the mechanisms responsible for these effects remain poorly defined. Through analysis of a large pan-cancer metagenomic dataset, Mimpen, Battaglia, Parra-Martinez, and colleagues found that microbial metabolic pathways were highly conserved across individuals and could therefore serve as suitable predictors of immunotherapy response. Several of these metabolic pathways correlated with immunotherapy efficacy, and metabolites generated through these pathways were shown to modulate immune activity in human model systems. Together, these findings identify microbial metabolic function as a key determinant of immunotherapy responsiveness and point towards new opportunities for microbiota-directed therapeutic strategies.See article, p. 95.Griffith and colleagues revealed that aryl hydrocarbon receptor (AHR) ligands found in cigarette smoke promote pancreatic dysplasia and pancreatic ductal adenocarcinoma (PDAC) progression via AHR-mediated polarization of CD4+ T cells. This resulted in the accumulation of IL22-producing TH22 cells and regulatory T cells, ultimately driving a blunted CD8+ T-cell effector response. Smokers demonstrated increased AHR activation in pancreatic parenchyma relative to nonsmokers, while resected PDAC tumors from smokers indicated increased regulatory T-cell accumulation compared to nonsmokers. These findings suggest that AHR ligands in cigarette smoke promote tumorigenesis and PDAC progression through dysregulation of immune responses, highlighting a potential mechanistic link between environmental AHR ligand exposure and pancreatic cancer.See article, p. 114.Metastatic progression in triple-negative breast cancer (TNBC) is closely linked to chromosomal instability (CIN), yet its molecular drivers remain unclear. Bai and colleagues uncovered a direct mechanistic link between CIN and the histone methyltransferase EZH2 in TNBC. Integrated chromatin and transcriptomic analyses showed that EZH2 repressed tankyrase (TNKS), subsequently stabilizing the centrosomal protein CPAP. This disruption promoted centrosome amplification, multipolar mitosis, and CIN. These CIN-driven abnormalities enhanced metastatic potential across TNBC models. Pharmacologic EZH2 inhibition restored TNKS expression, normalized centrosome integrity, mitigated CIN, and markedly suppressed metastasis. These findings define an epigenetically governed CIN-metastasis axis and highlight EZH2 inhibitors as potential antimetastatic therapies for aggressive breast cancers.See article, p. 135.p53 regulation in T cells and its contribution to cancer immunotherapy remain unclear. Yan and colleagues demonstrated that acetylation of the p53 carboxyl-terminal domain (CTD) activates T cell–intrinsic p53, thereby stimulating IFNγ pathway signaling, driving CD8+ T cell recruitment, and enhancing antitumor responses during immunotherapy. Analysis of acetylation-deficient and acetylation-mimetic knock-in mouse models indicated that p53 acetylation is critical in promoting CD8+ T cell–dependent tumor control. Ifng was a direct transcriptional target of p53, representing a p53–IFNγ feedback circuit in T cells. These findings define T cell–intrinsic p53 as a key immune regulator that potentiates immunotherapy efficacy.See article, p. 155.